Log in to search using one of your social media accounts:

 

Washington University and Harvard Medical School report positive topical immunotherapy trial results
The Washington University School of Medicine in St. Louis and Harvard Medical School have reported positive results from a clinical study of combination of two topical drugs, cream formulation of topical 5-fluorouracil and calcipotriol, to treat earl … (Source: Drug Development Technology)
Source: Drug Development Technology - November 23, 2016 Category: Pharmaceuticals Source Type: news

Topical immunotherapy combo effective against early skin cancer
Researchers from the Washington University School of Medicine and Harvard Medical School have shown that a combination of 2 topical drugs can trigger an immune response against precancerous skin lesions. The study was published yesterday in The Journal of Clinical Investigation. The 2 drugs, calcipotriol and 5-fluorouracil, have been in use for years – topical 5-fluorouracil is prescribed to treat actinic keratosis. Calcipotriol is indicated by the FDA for psoriasis, an autoimmune disorder that presents with red, scaly patches of skin. The researchers combined the 2 drugs and evaluated the combination&rsquo...
Source: Mass Device - November 22, 2016 Category: Medical Equipment Authors: Sarah Faulkner Tags: Drug-Device Combinations Oncology Pharmaceuticals Research & Development Harvard Medical School Washington University Source Type: news

Taclonex (Calcipotriene and Betamethasone Dipropionate) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - November 22, 2016 Category: Drugs & Pharmacology Source Type: news

Taclonex Scalp (Calcipotriene and Betamethasone Dipropionate Topical Suspension) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 6, 2016 Category: Drugs & Pharmacology Source Type: news

LEO Pharma recieves scientific approval of Enstilar® for the treatment of psoriasis in EU
The marketing approval of Enstilar® would make it the first fixed combination topical foam treatment for people living with psoriasis vulgaris in the EU (Source: Pharmacy Europe)
Source: Pharmacy Europe - March 21, 2016 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Practical therapeutics Legislation & regulation Dermatology Patient care calcipotriol/betamethasone dipropionate enstilar fixed combination topical foam Latest News psoriasis vulgaris Source Type: news

International study shows improved outcomes for psoriasis patients
Interim results from one of the largest and longest clinical trials ever conducted for a topical treatment in psoriasis* showed that after eight weeks of treatment with calcipotriol/betamethasone dipropionate (Daivobet® gel), the treatment was highly efficacious, preferred by patients and improved patients' and the physicians’ assessments of disease severity. (Source: Pharmacy Europe)
Source: Pharmacy Europe - October 29, 2014 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Clinical trials Practical therapeutics Rheumatology Patient care calcipotriol/betamethasone dipropionate Latest News psoriasis Source Type: news

Lipidor announces positive results from Phase I/IIa psoriasis study
Drug delivery company Lipidor, 50% owned by Karolinska Development, has reported positive results from Phase I/IIa psoriasis study of Akvano/calcipotriol spray formulation, a water-free spray formulation containing vitamin D derivative calcipotriol. (Source: Drug Development Technology)
Source: Drug Development Technology - August 27, 2013 Category: Pharmaceuticals Source Type: news